Sitagliptin - Wikipedia
Mechanism of action. Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones released in response to a meal. [28] .
Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment ... - UpToDate
2023年4月27日 · This topic will review the mechanism of action and therapeutic utility of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. GLP-1 receptor agonists are discussed separately.
What is Januvia used for and how does it work? - Drugs.com
2024年5月7日 · Januvia (sitagliptin), from Merck, works by targeting two key problems in type 2 diabetes: it increases insulin production in the pancreas and decreases glucose overproduction in the liver. When used in addition to diet and exercise, Januvia has been shown to improve blood sugar control (your A1C).
Sitagliptin: Uses, Interactions, Mechanism of Action
Mechanism of action. Inhibition of DPP-4 by sitagliptin slows DPP-4 mediated inactivation of incretins like GLP-1 and GIP Label,2. Incretins are released throughout the day and upregulated in response to meals as part of glucose homeostasis Label,4.
SitaGLIPtin: Dosage, Mechanism/Onset of Action, Half-Life
2020年2月10日 · Mechanism of Action. Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg, glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and ...
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion. In clinical studies it is weight neutral. This article gives an overview of the mechanism of action, the pharmacology, and the clinical efficacy and safety of sitagliptin in …
JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Sitagliptin (Januvia) | Top Drugs: Their History, Pharmacology, …
The efficacy of all the antidiabetic drugs can be monitored by measuring glycosylated hemoglobin (HaA1c) as a long term marker of elevated blood glucose. The amount of HaA1c reflects the average level over the last 120 days, the life span of a red blood cell, and should remain below 7%.
Januvia: Package Insert - Drugs.com
2024年10月2日 · 12.1 Mechanism of Action. Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones.
Sitagliptin - an overview | ScienceDirect Topics
2010年4月5日 · Its mechanism of action is through inhibition of dipeptidyl peptidase-4 (DPP-4), an enzyme that acts to degrade and inactivate glucagon-like peptide-1 (GLP-1). The elevated GLP-1 level in response to sitagliptin results in increased insulin release after meals, and improved glucose tolerance.